Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma

Clinical trial NCT01665417 · UNKNOWN

Trial details

NCT number: NCT01665417
Sponsor: Betta Pharmaceuticals Co., Ltd.
Status: UNKNOWN
Phase: Phase 4
Study type: INTERVENTIONAL

EGFR Positive Non-small Cell Lung Cancer Adenocarcinoma

Start date: 2012-08-01
Primary completion: 2017-07-01
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.